ErgoD2 Achieves Important Safety Milestone for Entia Biosciences
2/1/2012 9:09:45 AM
SHERWOOD, Ore., Feb. 1, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) announced today that it has successfully completed an acute oral toxicity study (LD50) with its proprietary ErgoD2™ whole-food formulation. ErgoD2™ is a 100% USDA organic formulation from mushrooms that are enhanced with the Company's patent pending UV light technology and contain naturally high concentrations L-Ergothioneine and Ergocalciferol (vitamin D2). ENTIA currently uses this formulation in its Groh™ hair and nail nutritional supplement and in its new line of ErgoD2™ branded medical foods that it intends to offer to healthcare providers treating patients with anemia, diabetes, and potentially other serious conditions. In August, ENTIA announced it had entered into a research agreement with Dr. Jack Rogers, Ph.D., Associate Professor of Psychiatry and Neuroscience at Harvard Medical School and Director of the Neurochemistry Laboratory at Massachusetts General Hospital, to evaluate the therapeutic and prophylactic potential of ErgoD2™ as a dietary therapy or as a palliative therapy for Parkinson's disease patients. Successful completion of the LD50 is an important milestone for the commencement of human trials and ENTIA's medical foods launch.
comments powered by